iShares Health Innovation Active ETF (BMED)

The iShares Health Innovation Active ETF emerged as part of iShares’ suite of thematic equity funds designed for investors who want to own companies driving specific industry transformations. BMED focuses on the health-care sector, specifically companies behind innovation in areas such as gene therapy, precision medicine, digital health platforms, and next-generation medical devices. Rather than tracking a passive index, BMED uses active management to select individual health-care equities the fund manager believes will outperform.

The rise of thematic and active health-care funds

For decades, health-care investors had few choices beyond broad sector index funds tracking the full universe of pharmaceutical, biotech, medical device, and hospital-operator stocks. In the 2010s, demand grew for more focused products that would isolate high-growth subsectors or companies backed by conviction-driven managers rather than index rules. iShares, owned by BlackRock, responded by building a suite of thematic ETFs, including BMED, that applied active stock-picking to specific innovation narratives within traditional sectors.

BMED positioned itself at the intersection of health care and innovation — not trying to track a passive health-care index, but rather assembling a portfolio of companies the manager believed would benefit most from ongoing shifts toward genetic medicine, real-world digital data, and novel device technologies.

The manager’s mandate and stock selection

BMED is actively managed, which means a human portfolio manager (or team) makes the day-to-day and month-to-month decisions about what to own. Unlike a passive index fund constrained by the rules of its benchmark, BMED’s manager has full discretion to overweight, underweight, or omit companies based on conviction about their innovation prospects and competitive positioning. The manager’s job is to find the subset of the health-care universe most likely to deliver above-market returns given the chosen innovation thesis.

This active approach allows the fund to concentrate in smaller, higher-risk companies early in their commercial life or to tilt toward established players entering new therapeutic areas. A passive health-care index would weight by market capitalisation, automatically overweighting Merck or Johnson & Johnson; BMED’s manager can choose a different weighting if they believe a smaller biotech company or a device innovator offers better returns relative to risk.

What “health innovation” means in practice

BMED’s portfolio typically includes companies across several overlapping categories. Biotechnology firms developing gene therapies, monoclonal antibodies, and cell-based treatments represent a core holding. Medical-device makers building diagnostics, wearable sensors, and surgical robotics are common. Digital-health platforms — companies enabling remote patient monitoring, AI-driven diagnosis, or electronic health records — also appear. And established pharmaceutical companies developing personalized medicines or entering new categories count as innovation plays.

The fund’s specific weightings change over time as the manager rotates between what seem like the highest-conviction ideas. The prospectus and fund documents outline the manager’s approach, but the actual portfolio details are published in near-real-time on iShares’ website.

Costs and the performance tradeoff

Active management costs money. BMED carries an expense ratio higher than a passive health-care index ETF would — the manager’s fees, the trading costs of executing the manager’s trades, and the compliance overhead all add up. For this higher fee, investors are betting that the manager’s stock-picking skill will outperform the index by more than the fee drag — a historically difficult bet. Studies of active fund managers show that most do not beat their benchmarks after fees over long periods.

BMED’s performance relative to a passive health-care index is a useful barometer. If BMED has outperformed the broader health-care sector over a full market cycle, the active-management fee was money well spent. If it has underperformed, the investor is paying for something that did not add value.

Risk concentration and the innovation premium

Because BMED tilts toward innovation and smaller companies, it carries higher volatility than the broad health-care sector. Many of the companies in the portfolio are speculative — backed by a single drug candidate in clinical trials or a technology that has not yet proven itself in the marketplace. This concentration risk means that BMED can outperform sharply in bull markets for health-care innovation and underperform just as sharply if sentiment turns against biotech or digital health.

The fund’s inception and growth coincided with a period of strong venture and biotech funding, and its performance benefited from that tail wind. Investors should understand that the fund is a bet on the continued strength of health-care innovation investing, not a defensive position.

How to evaluate BMED

A prospective investor should read the fund’s prospectus to understand the manager’s stated strategy, examine the current portfolio to see what companies and subsectors are represented, and review several years of performance versus a health-care index benchmark. Comparing BMED’s returns to the Nasdaq Biotechnology Index or the S&P Health Care Select Sector Index reveals whether active management has added value. Finally, assessing the manager’s tenure and track record across other funds helps judge whether the individual or team driving BMED has a history of consistent outperformance.